Cellular Biomedicine, a biotechnology company developing cell-based therapies to address degenerative diseases and immunotherapies for cancer, recently announced they will present new clinical findings at the 5th World Congress on Cancer Therapy, taking place on September 28, 2015 in Atlanta. Cellular Biomedicine’s presentation will include data from a Phase I clinical trial for the company’s Epidermal Growth Factor (EGFR) targeted Chimeric Antigen Receptor-Modified T-Cells (CAR-T) Immunotherapy for patients with Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.
Cell-based therapies consist of using cellular material as an agent inside the patients’ body. Cellular Biomedicine aims to develop safe and effective cellular therapies based on their expansive cellular platforms. In their therapeutic portfolio, they have developed Cancer Vaccines, Human adipose-derived mesenchymal progenitor cells (“haMPC”) for the treatment of joint and autoimmune diseases, and both Chimeric Antigen Receptor T cells (“CAR-T”) and anti-PD-1 Technologies to treat cancer.
Chimeric Antigen Receptors are engineered receptors that mimic a certain specificity within an immunologic cell. These are the typical receptors used to graft the specificity of a monoclonal antibody on a T Cell, and clinical trials have been conducted to verify the effectiveness of the engineered CAR-T in the treatment of patients with EGFR (HER-1) expressing advanced relapsed NSCLC.
The following includes details on the conference and Cellular Biomedicine’s presentation schedule:
Conference: 5th World Congress on Cancer Therapy, September 28-30, 2015 Atlanta, Georgia, USA
Title: EGFR (HER-1)-targeted Chimeric Antigen Receptor-Modified T-Cells Immunotherapy for Patients with Advanced or Relapsed/Refractory Solid Tumors
Oral Presentation: Scientific Program, September 28, 2015 18:05-18:25
Location: Hilton Atlanta Airport
Presenter: Wei Dong Han, MD, PhD, Chinese PLA General Hospital
The presentation is expected to expand on the data that will be presented at the European Cancer Congress poster presentation, which will be held in Vienna two days before on September 26, providing more insights into the phase 1 of CAR-T trial. This trial was designed and conducted by Chinese PLA General Hospital (“PLAGH”, Beijing), and led by Principal Investigator Wei Dong Han, MD, PhD, head of PLAGH’s cancer immunotherapy department.
From the previous positive clinical data from Phase 1 trials using CAR-T constructs against CD19, CD20 and CD30 for late-stage blood cancers, expectations are high and the scientific community must be enthusiastic about these first results.
Read more about the latest news concerning NCLC here.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?